Egis Pharmaceuticals
Egis Pharmaceuticals is a 110-year-old Hungarian vertically integrated generic pharmaceutical manufacturer, producing 653 products across 158 active ingredients and selling to pharmacies, physicians, and pharmaceutical partners in 100 countries under the Servier Group.
- Company typePrivate
- Founded1913
- HeadquartersBudapest, Hungary
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Egis Pharmaceuticals does
Egis Pharmaceuticals PLC (legal name: Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság) is a Hungarian pharmaceutical manufacturer founded in 1913 from the predecessor Dr. Wander Gyógyszer- és Tápszergyár, headquartered in Budapest with manufacturing operations across two Budapest sites and one in Körmend. The company is a privately held subsidiary of France's Servier Group and ranks as Hungary's 29th-largest employer. Egis operates a fully vertically integrated pharmaceutical value chain spanning R&D, active pharmaceutical ingredient (API) development and manufacturing, finished dosage form production (tablets, injections, ointments, suppositories, syrups), packaging, and sales across cardiovascular, central nervous system, diabetology, dermatology, gastroenterology, oncology, and women's health therapeutic areas. Its portfolio comprises 653 products across 177 product families derived from 158 active ingredients.
The company's manufacturing technology is built around cGMP-compliant organic chemical synthesis spanning more than 30 reaction types — including catalytic hydrogenation, Grignard, Friedel-Crafts, Mannich, asymmetric hydrogenation, and chiral resolution — using reactor scales from 630L to 10,000L and specialized equipment such as tantalum-coated reactors and short path three-stage distillation. A distinctive capability is highly potent (HP) API handling at OEB4 (OEL < 10 μg) in transparent closed isolators with a dedicated GMP production line providing approximately 600 kg of annual capacity. Facilities hold accreditations from FDA (since 1976), EDQM, PMDA, KFDA, and ANVISA, and comply with ICH Q7, Q11, Q2(R1), Q1A(R2), Q3D, and M7 guidelines — collectively enabling market access across the US, EU, Japan, South Korea, and Brazil.
Egis makes money through three revenue streams: sale of in-house generic pharmaceutical products, licensing of products and technologies to partners, and — since 2023 — contract development and manufacturing services (CDMO) for pharmaceutical partners globally, marketed as Egis Pharma Services. Distribution reaches 100 countries via 17 wholly-owned subsidiaries (including in Poland, Russia, the Baltic states, CIS, Caucasus, and Vietnam) and partner networks in remaining markets. End customers are healthcare professionals and pharmacies; CDMO clients are pharmaceutical companies requiring cGMP-compliant API development and manufacturing support.
Egis Pharmaceuticals firmographics
Firmographics- Name
- Egis Pharmaceuticals
- Legal name
- Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság
- Website
- https://hu.egis.health
- Company type
- Private
- Founded year
- 1913
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Egis Pharmaceuticals is a 110-year-old Hungarian vertically integrated generic pharmaceutical manufacturer, producing 653 products across 158 active ingredients and selling to pharmacies, physicians, and pharmaceutical partners in 100 countries under the Servier Group.
- Ownership category
- akta.pro rank
Egis Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)
- akta.pro secondary industries
- Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)
Keywords
Where Egis Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Budapest
- HQ country
- Hungary
- HQ region
- Europe
Offices4 records
Markets served
Egis Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Generic Pharmaceutical Products: Sale of generic pharmaceutical products manufactured in-house. Portfolio of 653 products across 177 product families from 158 active ingredients. Products include cardiovascular, CNS, and other therapeutic categories sold in 100 countries.
- Contract Manufacturing Services: API contract development and manufacturing services offered to pharmaceutical partners. Services include process development, scale-up, and commercial API production under cGMP. Started in 2023.
- Licensing Activities: Licensing of pharmaceutical products and technologies to partners in various markets.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Egis Pharmaceuticals product offering
Product offeringCore offering
Egis manufactures and distributes generic pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms — tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups) — across cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas, as well as a portfolio of OTC consumer health products. The company operates the full pharmaceutical value chain from API development and manufacturing through finished product manufacturing, packaging, sales, marketing, and licensing, supported by FDA-, EDQM-, PMDA-, KFDA-, and ANVISA-accredited cGMP facilities.
Product overview
Egis Pharmaceuticals is a pharmaceutical company with a comprehensive portfolio spanning active pharmaceutical ingredients (APIs) and finished dosage forms including tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups). The company manufactures 653 products organized into 177 product families derived from 158 different active ingredients, distributed to over 100 countries. Key therapeutic areas include cardiovascular (heart and vascular) and central nervous system, supplemented by diabetes, dermatology, and wound care. Egis also operates three Hungarian manufacturing sites (Budapest Keresztúri út for API production, Budapest Bökényföldi út for injectables and packaging, and Körmend for tablets and galenic products) and offers contract development and manufacturing services for pharmaceutical partners, including active ingredient development and manufacturing for both traditional and highly potent compounds.
Differentiator
Problem solved
Functional benefit
Brands
- Egis Pharma Services: Contract manufacturing and contract development services for active pharmaceutical ingredients offered to pharmaceutical partners.
Products and services
- Pharmaceutical Products Portfolio Core portfolio of 653 generic pharmaceutical products across 177 product families derived from 158 active ingredients, including APIs and finished dosage forms (tablets, injections, galenic preparations such as ointments, suppositories, solutions, syrups), distributed to 100 countries. Intended for healthcare professionals, pharmacies, and patients in cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas.
- Cardiovascular Pharmaceuticals Generic prescription pharmaceutical products for the cardiovascular therapeutic area (heart and vascular diseases), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives to physicians and pharmacists.
- Central Nervous System Pharmaceuticals Generic prescription pharmaceutical products for central nervous system disorders (neurological and psychiatric conditions), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives.
- Crila (OTC anti-diarrhea) Over-the-counter anti-diarrhea product available without prescription through Hungarian pharmacies.
- Reparon (OTC hemorrhoid treatment) Over-the-counter hemorrhoid treatment available without prescription through Hungarian pharmacies.
- Betadine (OTC skin disinfection) Over-the-counter skin disinfection product available through Hungarian pharmacies.
- Telviran (OTC herpes treatment) Over-the-counter herpes treatment available through Hungarian pharmacies.
- Ambroxol Egis (OTC respiratory) Over-the-counter respiratory medication for acute and chronic respiratory conditions with mucus secretion, available through Hungarian pharmacies.
- Paxirasol (OTC respiratory) Over-the-counter respiratory product for cough, asthma, and bronchitis to help clear airways, available through Hungarian pharmacies.
- Egis Pharma Services Contract development and manufacturing services (CDMO) for active pharmaceutical ingredients (APIs) offered to pharmaceutical partners globally under cGMP, covering route scouting, synthesis development, scale-up, and commercial API production including highly potent compounds. Brand sub-brand of Egis.
- Active Ingredient Contract Development Contract development services for active pharmaceutical ingredients including both traditional and highly potent (HP) compounds, with Budapest facilities featuring isolators for safe handling under cGMP.
- Active Ingredient Contract Manufacturing Contract manufacturing of intermediates and active pharmaceutical ingredients using organic chemical synthesis with GMP-compliant processes at Budapest facilities, with reactor capacity from 630 L to 10,000 L.
- HP Drug Substance Development and Manufacturing Highly potent drug substance development and GMP manufacturing with OEL levels between 1-10 micrograms (OEB4), including synthesis development, scale-up, and isolated production; dedicated production line capacity ~600 kg/year.
- Chemical Manufacturing Services Large-scale chemical synthesis manufacturing services including aminolysis, Grignard reactions, nitration, hydrogenation, Friedel-Crafts reactions, and other specialized organic chemistry processes performed under cGMP.
Quantifiable outcome
- Products reach 100 countries globally
- +3 more outcomes
Companies that use Egis Pharmaceuticals
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Egis Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Egis Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Pharmaceutical Industry Partners (unspecified)corePharmaceutical partners for whom Egis provides contract development and manufacturing services for active pharmaceutical ingredients. Services include route scouting, synthesis development, scale-up, and commercial API production under cGMP conditions.
- Regulatory Authorities (FDA, EDQM, PMDA, KFDA, ANVISA)coreAccreditation and audit relationships with major regulatory authorities worldwide. Successfully passed comprehensive audits and received accreditation from FDA (USA, first in 1976), EDQM (EU), PMDA (Japan), KFDA (South Korea), ANVISA (Brazil).
- Healthcare Professionals and Healthcare OrganizationscoreEgis engages with healthcare professionals (physicians, pharmacists) for product promotion, clinical collaboration, and transparency reporting under EFPIA Transparency Code. Healthcare organizations receive support and attend company-organized events.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Egis Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Alvotech: Iceland-based biosimilar-focused manufacturer with vertically integrated development and manufacturing capabilities. Comparable to Egis's higher-end API capabilities (HP, isolator, advanced chemistry) and as a potential adjacent competitor for sophisticated contract manufacturing opportunities.
Direct peers
- Recipharm: European CDMO offering contract development and manufacturing of APIs and finished dosage forms. Comparable to Egis's newly launched Egis Pharma Services API CDMO business, competing for the same pharmaceutical partner customers.
- Stada Arzneimittel: German-headquartered European generics and consumer healthcare company with broad portfolio across cardiovascular, CNS, and OTC categories. Comparable to Egis as a European-focused, vertically organized generic and OTC manufacturer with multi-country distribution.
- KRKA: Slovenian generic pharmaceutical manufacturer with strong CEE/CIS distribution, vertically integrated API production, and broad therapeutic coverage. Highly comparable to Egis in scale, footprint, and generics-led business model.
- Polpharma: Polish pharmaceutical manufacturer and one of the largest CEE generic producers, with vertically integrated API and finished product manufacturing. Comparable to Egis on regional scale, therapeutic breadth, and integrated generics model.
- Gedeon Richter: Hungarian-headquartered pharmaceutical company with vertically integrated generic and specialty pharma operations across CEE and Western Europe. Closely comparable to Egis on geography, therapeutic focus (CNS, cardiovascular, women's health), and integrated API-to-finished-product model.
- Zentiva: Czech-headquartered European generic pharmaceutical company (formerly Sanofi generics) with strong CEE presence and broad finished-product portfolio. Comparable to Egis in CEE-centric generics focus and finished dosage-form manufacturing.
Broad incumbents
- Sandoz: Novartis's standalone generics and biosimilars division with European heritage and broad API and finished product operations. Comparable to Egis on European generics distribution and biosimilar/specialty optionality, though at materially larger scale.
- Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong MENA, US, and Europe presence. Comparable to Egis on vertically integrated generic manufacturing and broad geographic distribution, though with greater US exposure.
- Teva Pharmaceutical Industries: Global generics and specialty pharma leader with extensive API and finished product operations. Comparable to Egis as a broader incumbent offering overlapping generic categories and contract manufacturing services, but at much larger scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Egis Pharmaceuticals social profiles
Digital presenceEgis Pharmaceuticals compliance and trust
Trust signalCompliance14 records
Egis Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Egis Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Egis Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries4 records
Egis Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Egis Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Egis Pharmaceuticals
What does Egis Pharmaceuticals do?
Egis manufactures and distributes generic pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms — tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups) — across cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas, as well as a portfolio of OTC consumer health products. The company operates the full pharmaceutical value chain from API development and manufacturing through finished product manufacturing, packaging, sales, marketing, and licensing, supported by FDA-, EDQM-, PMDA-, KFDA-, and ANVISA-accredited cGMP facilities.
Is Egis Pharmaceuticals a public or private company?
Egis Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Egis Pharmaceuticals founded?
Egis Pharmaceuticals was founded in 1913. It employs 1,001 to 5,000 people.
Where is Egis Pharmaceuticals based?
Egis Pharmaceuticals is headquartered in Budapest, Hungary, in the Europe region.
How does Egis Pharmaceuticals make money?
Three revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are contract Manufacturing Services and licensing Activities.
Who are Egis Pharmaceuticals's main competitors?
Alvotech is listed as an emerging player. Direct peers are Recipharm, Stada Arzneimittel, KRKA, Polpharma, Gedeon Richter and Zentiva. Broad incumbents are Sandoz, Hikma Pharmaceuticals and Teva Pharmaceutical Industries.
Does Egis Pharmaceuticals have an API?
No public API is recorded for Egis Pharmaceuticals.
What industry is Egis Pharmaceuticals in?
Egis Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply), with a secondary code of CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325412 and its SIC code is 2834.